Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free BMY Stock Alerts

Bristol Myers Squibb (BMY) Financials

Bristol Myers Squibb logo
$56.56 -0.39 (-0.69%)
Closing price 05/6/2026 03:59 PM Eastern
Extended Trading
$56.57 +0.02 (+0.03%)
As of 08:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Bristol Myers Squibb

Annual Income Statements for Bristol Myers Squibb

This table shows Bristol Myers Squibb's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 1,565 4,457 1,007 4,920 3,439 -9,015 6,994 6,327 8,025 -8,948 7,054
Consolidated Net Income / (Loss)		 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933 7,055
Net Income / (Loss) Continuing Operations		 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933 7,056
Total Pre-Tax Income 		2,077 5,915 5,131 5,968 4,975 -6,871 8,098 7,713 8,440 -8,379 9,328
Total Operating Income		 1,890 4,467 3,446 5,114 5,913 -9,185 7,378 8,289 7,282 -7,486 10,002
Total Gross Profit		 12,651 14,458 14,762 16,094 18,067 30,745 35,286 35,207 33,400 20,959 30,537
Total Revenue		 16,560 19,427 20,776 22,561 26,145 42,518 46,385 46,159 45,006 48,300 48,194
Operating Revenue		 14,045 19,427 20,776 22,561 26,145 42,518 46,385 46,159 45,006 48,300 48,194
Total Cost of Revenue		 3,909 4,969 6,014 6,467 8,078 11,773 11,099 10,952 11,606 27,341 17,657
Operating Cost of Revenue		 3,909 4,969 6,014 6,467 8,078 11,773 11,099 10,952 11,606 27,341 17,657
Total Operating Expenses		 10,761 9,991 11,316 10,980 12,154 39,930 27,908 26,918 26,118 28,445 20,535
Selling, General & Admin Expense		 4,841 4,979 4,751 4,551 4,871 7,661 7,690 7,814 7,772 8,414 7,267
Research & Development Expense		 5,920 5,012 6,468 6,332 6,148 10,048 10,195 9,509 9,299 11,159 9,951
Amortization Expense		 - - 97 97 1,135 9,688 10,023 9,595 9,047 8,872 3,317
Total Other Income / (Expense), net		 187 1,448 1,685 854 -938 2,314 720 -576 1,158 -893 -674
Other Income / (Expense), net		 187 1,448 1,685 854 -938 2,314 720 -576 1,158 -893 -674
Income Tax Expense		 446 1,408 4,156 1,021 1,515 2,124 1,084 1,368 400 554 2,272
Net Income / (Loss) Attributable to Noncontrolling Interest		 66 50 -32 27 21 20 20 18 15 15 2.00
Basic Earnings per Share		 $0.94 $2.67 $0.61 $3.01 $2.02 ($3.99) $3.15 $2.97 $3.88 ($4.41) $3.47
Weighted Average Basic Shares Outstanding		 1.67B 1.67B 1.65B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B 2.04B
Diluted Earnings per Share		 $0.93 $2.65 $0.61 $3.01 $2.01 ($3.99) $3.12 $2.95 $3.86 ($4.41) $3.46
Weighted Average Diluted Shares Outstanding		 1.67B 1.67B 1.65B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B 2.04B
Weighted Average Basic & Diluted Shares Outstanding		 1.67B 1.67B 1.65B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B 2.04B
Cash Dividends to Common per Share		 $1.49 $1.53 $1.57 $1.61 $1.68 $1.84 $2.01 $2.19 $2.31 $2.42 $2.49

Quarterly Income Statements for Bristol Myers Squibb

This table shows Bristol Myers Squibb's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 1,928 1,762 -11,911 1,680 1,211 72 2,456 1,310 2,201 1,087 2,677
Consolidated Net Income / (Loss)		 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313 2,195 1,085 2,678
Net Income / (Loss) Continuing Operations		 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313 2,195 1,086 2,679
Total Pre-Tax Income 		2,137 1,674 -11,516 1,286 1,676 175 2,971 1,773 3,114 1,470 3,240
Total Operating Income		 1,879 1,303 -11,435 1,559 1,910 480 3,309 2,266 3,006 1,421 3,271
Total Gross Profit		 8,380 8,132 -4,016 8,802 8,673 7,500 7,980 7,389 8,154 7,014 7,974
Total Revenue		 10,966 11,477 11,865 12,201 11,892 12,342 11,201 12,269 12,222 12,502 11,489
Operating Revenue		 10,966 11,477 11,865 12,201 11,892 12,342 11,201 12,269 12,222 12,502 11,489
Total Cost of Revenue		 2,586 3,345 15,881 3,399 3,219 4,842 3,221 4,880 4,068 5,488 3,515
Operating Cost of Revenue		 2,586 3,345 15,881 3,399 3,219 4,842 3,221 4,880 4,068 5,488 3,515
Total Operating Expenses		 6,501 6,829 7,419 7,243 6,763 7,020 4,671 5,123 5,148 5,593 4,703
Selling, General & Admin Expense		 2,003 2,073 2,367 1,928 1,983 2,136 1,584 1,713 1,789 2,181 1,617
Research & Development Expense		 2,242 2,478 2,695 2,899 2,374 3,191 2,257 2,580 2,528 2,586 2,649
Amortization Expense		 2,256 2,278 2,357 2,416 2,406 1,693 830 830 831 826 437
Total Other Income / (Expense), net		 258 371 -81 -273 -234 -305 -339 -494 108 51 -32
Other Income / (Expense), net		 258 371 -81 -273 -234 -305 -339 -494 108 51 -32
Income Tax Expense		 203 -88 392 -398 461 99 509 460 919 384 561
Net Income / (Loss) Attributable to Noncontrolling Interest		 6.00 - 3.00 4.00 4.00 4.00 6.00 2.00 -6.00 - 1.00
Basic Earnings per Share		 $0.94 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.21 $0.64 $1.08 $0.54 $1.31
Weighted Average Basic Shares Outstanding		 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B 2.04B 2.04B 2.04B
Diluted Earnings per Share		 $0.93 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.20 $0.64 $1.08 $0.54 $1.31
Weighted Average Diluted Shares Outstanding		 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B 2.04B 2.04B 2.04B
Weighted Average Basic & Diluted Shares Outstanding		 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B 2.04B 2.04B 2.04B
Cash Dividends to Common per Share		 $0.57 - $0.60 $0.60 - - $0.62 $0.62 - - $0.63

Annual Cash Flow Statements for Bristol Myers Squibb

This table details how cash moves in and out of Bristol Myers Squibb's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3,186 1,852 1,132 1,531 5,909 2,153 -657 -4,991 2,194 -1,172 -129
Net Cash From Operating Activities		 2,105 3,058 5,275 7,066 8,210 14,052 16,207 13,066 13,860 15,190 14,156
Net Cash From Continuing Operating Activities		 2,105 3,058 5,275 7,066 8,210 14,052 16,207 13,066 13,860 15,190 14,156
Net Income / (Loss) Continuing Operations		 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933 7,055
Consolidated Net Income / (Loss)		 1,631 4,507 975 4,947 3,460 -8,995 7,014 6,345 8,040 -8,933 7,055
Depreciation Expense		 376 382 789 637 1,746 10,380 10,686 10,276 9,760 9,600 4,011
Non-Cash Adjustments To Reconcile Net Income		 935 -644 677 1,034 -1,453 12,454 1,703 1,412 1,262 15,802 4,159
Changes in Operating Assets and Liabilities, net		 -1,082 -1,356 2,598 262 2,769 213 -3,196 -4,967 -5,202 -1,279 -1,069
Net Cash From Investing Activities		 -1,572 1,480 -66 -2,000 -9,913 -10,859 -538 -1,062 -2,295 -21,352 -4,132
Net Cash From Continuing Investing Activities		 -1,572 1,480 -66 -2,000 -9,913 -10,859 -538 -1,062 -2,295 -21,352 -4,132
Purchase of Property, Plant & Equipment		 -820 -1,215 -1,055 -951 -836 -753 -973 -1,118 -1,209 -1,248 -1,311
Acquisitions		 -1,111 -359 -726 -2,372 -24,777 -13,084 -1,610 -4,286 -1,169 -21,821 -3,944
Purchase of Investments		 -3,143 -3,089 -5,419 -2,305 -3,961 -4,172 -5,478 -3,592 -1,774 -769 -2,000
Divestitures		 708 1,334 736 1,249 15,852 870 748 1,305 909 1,099 1,071
Sale and/or Maturity of Investments		 2,794 4,809 6,398 2,379 3,809 6,280 6,775 6,629 948 1,387 2,052
Net Cash From Financing Activities		 -3,624 -2,653 -4,077 -3,535 7,621 -1,151 -16,224 -16,962 -9,416 5,127 -10,348
Net Cash From Continuing Financing Activities		 -3,624 -2,653 -4,077 -3,535 7,621 -1,151 -16,224 -16,962 -9,416 5,127 -10,348
Repayment of Debt		 -2,406 0.00 -1,246 -602 -9,178 -2,475 -5,541 -11,237 -3,999 -5,774 -10,915
Repurchase of Common Equity		 0.00 -231 -2,469 -320 -7,300 -1,546 -6,287 -8,001 -5,155 0.00 0.00
Payment of Dividends		 -2,477 -2,547 -2,577 -2,613 -2,679 -4,075 -4,396 -4,634 -4,744 -4,863 -5,045
Issuance of Debt		 1,259 125 2,215 0.00 26,778 6,945 0.00 5,926 4,455 15,870 5,740
Other Financing Activities, net		 - - - - - - - 984 27 -106 -128
Effect of Exchange Rate Changes		 -95 -33 - - -9.00 111 -102 -33 45 -137 195

Quarterly Cash Flow Statements for Bristol Myers Squibb

This table details how cash moves in and out of Bristol Myers Squibb's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -857 3,951 -2,185 -3,038 1,597 2,454 528 1,736 3,115 -5,508 -635
Net Cash From Operating Activities		 4,751 4,252 2,834 2,326 5,591 4,439 1,954 3,917 6,311 1,974 1,104
Net Cash From Continuing Operating Activities		 4,751 4,252 2,834 2,326 5,591 4,439 1,954 3,917 6,311 1,974 1,104
Net Income / (Loss) Continuing Operations		 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313 2,195 1,085 2,678
Consolidated Net Income / (Loss)		 1,934 1,762 -11,908 1,684 1,215 76 2,462 1,313 2,195 1,085 2,678
Depreciation Expense		 2,435 2,464 2,532 2,596 2,592 1,880 1,012 1,011 1,011 977 594
Non-Cash Adjustments To Reconcile Net Income		 418 498 12,723 748 333 1,998 128 1,679 409 1,943 505
Changes in Operating Assets and Liabilities, net		 -36 -472 -513 -2,702 1,451 485 -1,648 -86 2,696 -2,031 -2,673
Net Cash From Investing Activities		 -410 -1,346 -19,618 -1,319 -219 -196 -499 -473 -1,702 -1,458 -131
Net Cash From Continuing Investing Activities		 -410 -1,346 -19,618 -1,319 -219 -196 -499 -473 -1,702 -1,458 -131
Purchase of Property, Plant & Equipment		 -342 -330 -284 -262 -324 -378 -260 -361 -320 -370 -347
Acquisitions		 -326 -581 -20,053 -1,373 -348 -47 -78 -285 -1,874 -1,707 -65
Purchase of Investments		 -502 -717 -274 -84 -40 -371 -636 -621 -665 -78 -781
Divestitures		 247 241 241 270 255 333 243 270 279 279 312
Sale and/or Maturity of Investments		 513 41 752 130 238 267 232 524 878 418 750
Net Cash From Financing Activities		 -5,160 967 14,644 -4,023 -3,852 -1,642 -993 -1,836 -1,490 -6,029 -1,560
Net Cash From Continuing Financing Activities		 -5,160 967 14,644 -4,023 -3,852 -1,642 -993 -1,836 -1,490 -6,029 -1,560
Repayment of Debt		 -10 -2,353 83 -5,787 -2,652 -405 368 -585 -224 -10,474 -179
Payment of Dividends		 -1,191 -1,160 -1,212 -1,217 -1,216 -1,218 -1,258 -1,262 -1,263 -1,262 -1,283
Other Financing Activities, net		 41 25 -97 -6.00 16 -19 -103 11 -3.00 -33 -98
Effect of Exchange Rate Changes		 -38 78 -45 -22 77 -147 66 128 -4.00 5.00 -48

Annual Balance Sheets for Bristol Myers Squibb

This table presents Bristol Myers Squibb's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 31,748 33,707 33,551 34,986 129,944 118,481 109,314 96,820 95,159 92,603 90,038
Total Current Assets		 10,415 13,704 14,854 17,716 29,354 30,192 33,262 27,273 31,770 29,780 29,390
Cash & Equivalents		 2,385 4,237 5,421 6,911 12,346 14,546 13,979 9,123 11,464 10,346 10,209
Short-Term Investments		 1,885 2,113 1,391 1,848 3,047 1,285 2,987 130 816 513 464
Accounts Receivable		 4,299 5,543 6,300 5,747 7,685 8,501 9,369 9,886 10,921 10,747 11,414
Inventories, net		 1,221 1,241 1,166 1,195 4,293 2,074 2,095 2,339 2,662 2,557 2,690
Other Current Assets		 625 570 576 2,015 1,983 3,786 4,832 5,795 5,907 5,617 4,613
Plant, Property, & Equipment, net		 4,412 4,980 5,001 5,027 6,252 5,886 6,049 6,255 6,646 7,136 7,543
Total Noncurrent Assets		 16,921 15,023 13,696 12,243 94,338 82,403 70,003 63,292 56,743 55,687 53,105
Long-Term Investments		 4,660 2,719 2,480 1,775 767 433 - 0.00 364 320 396
Goodwill		 6,881 6,875 6,863 6,538 22,488 20,547 20,502 21,149 21,169 21,719 21,754
Intangible Assets		 1,419 1,385 1,210 1,091 63,969 53,243 42,527 35,859 27,072 23,307 19,103
Noncurrent Deferred & Refundable Income Taxes		 2,844 2,996 1,610 815 510 1,161 1,439 1,344 2,768 4,236 5,378
Other Noncurrent Operating Assets		 1,117 1,048 1,533 2,024 6,604 7,019 5,535 4,940 5,370 6,105 6,474
Total Liabilities & Shareholders' Equity		 31,748 33,707 33,551 34,986 129,944 118,481 109,314 96,820 95,159 92,603 90,038
Total Liabilities		 17,324 17,360 21,704 20,859 78,246 80,599 73,308 65,702 65,674 76,215 71,533
Total Current Liabilities		 8,017 8,841 9,563 10,654 18,304 19,080 21,868 21,890 22,262 23,774 23,417
Short-Term Debt		 139 992 987 1,703 3,346 2,340 4,948 4,264 3,119 2,046 2,261
Accounts Payable		 1,565 1,664 2,248 1,892 2,445 2,713 2,949 3,040 3,259 3,602 3,575
Other Current Liabilities		 - - - 7,059 12,513 14,027 13,971 14,586 15,884 18,126 17,581
Total Noncurrent Liabilities		 9,307 8,519 12,141 10,205 59,942 61,519 51,440 43,812 43,412 52,441 48,115
Long-Term Debt		 6,550 5,716 6,975 5,646 43,387 48,336 39,605 35,056 36,653 47,603 42,850
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 19 6,454 5,407 4,501 2,166 338 369 222
Other Noncurrent Operating Liabilities		 1,429 1,283 1,164 4,540 10,101 7,776 7,334 6,590 6,421 4,469 5,043
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14,424 16,347 11,847 14,127 51,698 37,882 36,006 31,118 29,485 16,388 18,506
Total Preferred & Common Equity		 14,266 16,177 11,741 14,031 51,598 37,822 35,946 31,061 29,430 16,335 18,473
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 14,266 16,177 11,741 14,031 51,598 37,822 35,946 31,061 29,430 16,335 18,472
Common Stock		 1,680 1,946 2,119 2,302 44,001 44,617 44,653 45,457 45,976 46,316 46,679
Retained Earnings		 31,613 33,513 31,160 34,065 34,474 21,281 23,820 25,503 28,766 14,912 16,896
Treasury Stock		 -16,559 -16,779 -19,249 -19,574 -25,357 -26,237 -31,259 -38,618 -43,766 -43,655 -43,579
Accumulated Other Comprehensive Income / (Loss)		 -2,468 -2,503 -2,289 -2,762 -1,520 -1,839 -1,268 -1,281 -1,546 -1,238 -1,524
Noncontrolling Interest		 158 170 106 96 100 60 60 57 55 53 33

Quarterly Balance Sheets for Bristol Myers Squibb

This table presents Bristol Myers Squibb's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 93,489 91,263 95,159 99,031 94,646 93,670 92,603 92,427 94,676 96,889 86,476
Total Current Assets		 28,074 27,632 31,770 28,669 26,890 28,075 29,780 30,783 33,222 35,630 27,208
Cash & Equivalents		 8,372 7,514 11,464 9,330 6,293 7,890 10,346 10,875 12,599 15,726 9,574
Short-Term Investments		 358 171 816 340 360 204 513 907 1,004 776 912
Accounts Receivable		 10,112 10,304 10,921 10,447 11,423 11,026 10,747 10,801 11,415 11,422 9,368
Inventories, net		 2,364 2,436 2,662 2,985 3,077 3,332 2,557 2,666 2,737 2,758 2,756
Other Current Assets		 6,868 7,207 5,907 5,567 5,737 5,623 5,617 5,534 5,466 4,948 4,597
Plant, Property, & Equipment, net		 6,355 6,481 6,646 6,750 6,845 6,903 7,136 7,213 7,373 7,349 7,658
Total Noncurrent Assets		 59,060 56,825 56,743 63,612 60,911 58,692 55,687 54,430 54,083 53,909 51,608
Long-Term Investments		 - - 364 367 357 324 320 344 346 406 366
Goodwill		 21,163 21,147 21,169 21,738 21,732 21,751 21,719 21,737 21,776 21,745 21,740
Intangible Assets		 31,303 28,950 27,072 32,760 29,428 26,964 23,307 22,486 21,378 20,465 18,244
Noncurrent Deferred & Refundable Income Taxes		 1,572 1,514 2,768 2,723 3,323 3,609 4,236 3,997 4,647 4,961 5,176
Other Noncurrent Operating Assets		 5,022 5,214 5,370 6,024 6,071 6,044 6,105 5,866 5,936 6,332 6,082
Total Liabilities & Shareholders' Equity		 93,489 91,263 95,159 99,031 94,646 93,670 92,603 92,427 94,676 96,889 86,476
Total Liabilities		 61,459 62,201 65,674 82,483 77,577 76,470 76,215 74,979 77,187 78,289 66,374
Total Current Liabilities		 20,150 23,462 22,262 25,822 23,265 22,638 23,774 24,070 27,528 28,136 19,158
Short-Term Debt		 3,020 5,467 3,119 6,190 3,531 1,078 2,046 3,554 4,715 4,509 2,308
Accounts Payable		 3,069 2,813 3,259 3,539 3,751 3,469 3,602 4,002 5,427 4,288 4,234
Other Current Liabilities		 14,061 15,182 15,884 16,093 15,983 18,091 18,126 16,514 17,386 19,339 12,616
Total Noncurrent Liabilities		 41,309 38,739 43,412 56,661 54,312 53,832 52,441 50,910 49,659 50,153 47,216
Long-Term Debt		 34,656 32,137 36,653 49,487 48,858 48,674 47,603 46,157 44,470 44,469 42,152
Noncurrent Deferred & Payable Income Tax Liabilities		 751 399 338 442 461 430 369 276 247 225 211
Other Noncurrent Operating Liabilities		 5,902 6,203 6,421 6,732 4,993 4,728 4,469 4,477 4,942 5,459 4,853
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 32,030 29,062 29,485 16,548 17,069 17,200 16,388 17,448 17,489 18,600 20,102
Total Preferred & Common Equity		 31,973 28,998 29,430 16,490 17,015 17,142 16,335 17,389 17,435 18,552 20,068
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 31,973 28,998 29,430 16,490 17,015 17,142 16,335 17,388 17,436 18,551 20,068
Common Stock		 45,591 45,141 45,976 45,947 46,058 46,188 46,316 46,303 46,426 46,557 46,666
Retained Earnings		 27,449 28,218 28,766 15,640 16,103 16,097 14,912 16,106 16,154 17,093 18,287
Treasury Stock		 -39,680 -43,075 -43,766 -43,697 -43,690 -43,675 -43,655 -43,597 -43,590 -43,586 -43,515
Accumulated Other Comprehensive Income / (Loss)		 -1,387 -1,286 -1,546 -1,400 -1,456 -1,468 -1,238 -1,424 -1,554 -1,513 -1,370
Noncontrolling Interest		 57 64 55 58 54 58 53 59 54 48 34

Annual Metrics And Ratios for Bristol Myers Squibb

This table displays calculated financial ratios and metrics derived from Bristol Myers Squibb's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 4.29% 17.31% 6.94% 8.59% 15.89% 62.62% 9.10% -0.49% -2.50% 7.32% -0.22%
EBITDA Growth		 -29.35% 139.66% -4.79% 10.32% 23.83% -58.27% 435.31% -4.23% 1.17% -93.29% 992.47%
EBIT Growth		 -12.77% 184.79% -13.25% 16.31% -16.64% -238.11% 217.86% -4.75% 9.43% -199.28% 211.33%
NOPAT Growth		 -32.78% 129.33% -80.76% 547.38% -2.99% -256.35% 199.39% 6.70% 1.73% -175.54% 244.38%
Net Income Growth		 -19.62% 176.33% -78.37% 407.38% -30.06% -359.97% 177.98% -9.54% 26.71% -211.11% 178.98%
EPS Growth		 -22.50% 184.95% -76.98% 393.44% -33.22% -298.51% 178.20% -5.45% 30.85% -214.25% 178.46%
Operating Cash Flow Growth		 -33.13% 45.27% 72.50% 33.95% 16.19% 71.16% 15.34% -19.38% 6.08% 9.60% -6.81%
Free Cash Flow Firm Growth		 -77.27% 74.34% 157.63% -7.51% -1,862.32% 105.28% 325.41% -38.86% 24.73% -130.28% 383.37%
Invested Capital Growth		 4.87% 14.80% -24.80% 4.04% 651.88% -12.13% -12.04% -3.79% -7.47% -3.10% -4.21%
Revenue Q/Q Growth		 0.18% 5.18% 1.00% 2.38% 8.16% 7.93% 2.02% -1.24% 0.16% 1.82% 0.33%
EBITDA Q/Q Growth		 -28.49% 30.78% -4.23% 12.14% -6.72% -71.74% 184.95% -0.28% -1.31% -63.04% 3.04%
EBIT Q/Q Growth		 -14.42% 33.85% -7.03% 15.64% -24.72% -299.10% 292.58% 0.09% -2.14% -21.79% 16.15%
NOPAT Q/Q Growth		 -28.02% 23.88% -77.20% 269.00% -30.79% -21,598.68% 227.79% -11.63% -5.45% -12.35% 10.94%
Net Income Q/Q Growth		 -11.65% 31.75% -76.80% 238.84% -39.06% -32,025.00% 230.25% -5.19% -3.17% -23.26% 16.69%
EPS Q/Q Growth		 -12.26% 32.50% -75.98% 234.44% -41.74% -1,275.86% 231.09% -3.91% -2.03% -22.84% 16.50%
Operating Cash Flow Q/Q Growth		 17.40% 22.37% -5.82% 52.68% -14.34% 9.12% 4.53% -5.44% 7.33% 1.25% -14.83%
Free Cash Flow Firm Q/Q Growth		 6.51% -14.79% 29.89% 44.05% -854.76% 105.52% 582.50% -17.82% 0.20% 23.27% -32.75%
Invested Capital Q/Q Growth		 -7.30% -0.19% -23.28% -10.38% 789.80% -1.68% -4.11% -2.58% -3.48% -6.28% 3.71%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.39% 74.42% 71.05% 71.34% 69.10% 72.31% 76.07% 76.27% 74.21% 43.39% 63.36%
EBITDA Margin		 16.29% 33.28% 29.63% 30.10% 32.16% 8.25% 40.50% 38.97% 40.44% 2.53% 27.68%
Operating Margin		 11.41% 22.99% 16.59% 22.67% 22.62% -21.60% 15.91% 17.96% 16.18% -15.50% 20.75%
EBIT Margin		 12.54% 30.45% 24.70% 26.45% 19.03% -16.16% 17.46% 16.71% 18.75% -17.35% 19.36%
Profit (Net Income) Margin		 9.85% 23.20% 4.69% 21.93% 13.23% -21.16% 15.12% 13.75% 17.86% -18.49% 14.64%
Tax Burden Percent		 78.53% 76.20% 19.00% 82.89% 69.55% 130.91% 86.61% 82.26% 95.26% 106.61% 75.63%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 21.47% 23.80% 81.00% 17.11% 30.45% 0.00% 13.39% 17.74% 4.74% 0.00% 24.36%
Return on Invested Capital (ROIC)		 12.47% 26.01% 5.34% 39.51% 8.82% -8.32% 9.41% 10.93% 11.78% -9.40% 14.09%
ROIC Less NNEP Spread (ROIC-NNEP)		 7.23% -21.94% -12.00% 8.15% 4.06% -16.22% 11.42% 9.29% 15.64% -20.66% 12.68%
Return on Net Nonoperating Assets (RNNOA)		 -1.38% 3.28% 1.57% -1.42% 1.69% -11.76% 9.58% 7.98% 14.76% -29.54% 26.35%
Return on Equity (ROE)		 11.09% 29.29% 6.92% 38.09% 10.51% -20.08% 18.99% 18.91% 26.53% -38.95% 40.44%
Cash Return on Invested Capital (CROIC)		 7.72% 12.23% 33.66% 35.55% -144.22% 4.59% 22.21% 14.79% 19.54% -6.25% 18.39%
Operating Return on Assets (OROA)		 6.34% 18.07% 15.26% 17.42% 6.03% -5.53% 7.11% 7.48% 8.79% -8.93% 10.21%
Return on Assets (ROA)		 4.98% 13.77% 2.90% 14.44% 4.20% -7.24% 6.16% 6.16% 8.38% -9.52% 7.73%
Return on Common Equity (ROCE)		 10.98% 28.98% 6.85% 37.80% 10.48% -20.05% 18.95% 18.87% 26.48% -38.86% 40.34%
Return on Equity Simple (ROE_SIMPLE)		 11.43% 27.86% 8.30% 35.26% 6.71% -23.78% 19.51% 20.43% 27.32% -54.69% 0.00%
Net Operating Profit after Tax (NOPAT)		 1,484 3,404 655 4,239 4,112 -6,430 6,390 6,819 6,937 -5,240 7,566
NOPAT Margin		 8.96% 17.52% 3.15% 18.79% 15.73% -15.12% 13.78% 14.77% 15.41% -10.85% 15.70%
Net Nonoperating Expense Percent (NNEP)		 5.24% 47.95% 17.35% 31.36% 4.76% 7.90% -2.01% 1.64% -3.86% 11.26% 1.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 9.68% 10.02% -7.94% 11.89%
Cost of Revenue to Revenue		 23.61% 25.58% 28.95% 28.66% 30.90% 27.69% 23.93% 23.73% 25.79% 56.61% 36.64%
SG&A Expenses to Revenue		 29.23% 25.63% 22.87% 20.17% 18.63% 18.02% 16.58% 16.93% 17.27% 17.42% 15.08%
R&D to Revenue		 35.75% 25.80% 31.13% 28.07% 23.52% 23.63% 21.98% 20.60% 20.66% 23.10% 20.65%
Operating Expenses to Revenue		 64.98% 51.43% 54.47% 48.67% 46.49% 93.91% 60.17% 58.32% 58.03% 58.89% 42.61%
Earnings before Interest and Taxes (EBIT)		 2,077 5,915 5,131 5,968 4,975 -6,871 8,098 7,713 8,440 -8,379 9,328
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 2,698 6,466 6,156 6,791 8,409 3,509 18,784 17,989 18,200 1,221 13,339
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.30 4.82 7.00 5.09 1.76 3.35 3.56 4.48 3.34 6.95 5.88
Price to Tangible Book Value (P/TBV)		 15.07 9.84 22.41 11.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5.43 4.01 3.96 3.16 3.48 2.98 2.76 3.01 2.18 2.35 2.25
Price to Earnings (P/E)		 57.45 17.48 81.62 14.51 26.47 0.00 18.32 21.98 12.25 0.00 15.39
Dividend Yield		 2.76% 3.26% 3.11% 3.66% 2.94% 3.28% 3.40% 3.30% 4.72% 4.29% 4.65%
Earnings Yield		 1.74% 5.72% 1.23% 6.89% 3.78% 0.00% 5.46% 4.55% 8.16% 0.00% 6.50%
Enterprise Value to Invested Capital (EV/IC)		 7.21 5.41 7.70 6.24 1.48 2.23 2.45 2.77 2.22 2.77 2.71
Enterprise Value to Revenue (EV/Rev)		 5.30 3.90 3.90 3.03 4.66 3.79 3.36 3.67 2.79 3.15 2.96
Enterprise Value to EBITDA (EV/EBITDA)		 32.55 11.71 13.15 10.06 14.47 45.95 8.29 9.41 6.89 124.48 10.69
Enterprise Value to EBIT (EV/EBIT)		 42.29 12.80 15.78 11.45 24.46 0.00 19.24 21.94 14.87 0.00 15.29
Enterprise Value to NOPAT (EV/NOPAT)		 59.18 22.25 123.65 16.11 29.60 0.00 24.38 24.81 18.09 0.00 18.85
Enterprise Value to Operating Cash Flow (EV/OCF)		 41.72 24.76 15.35 9.67 14.82 11.48 9.61 12.95 9.05 10.01 10.07
Enterprise Value to Free Cash Flow (EV/FCFF)		 95.66 47.31 19.63 17.91 0.00 45.46 10.32 18.34 10.90 0.00 14.44
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.46 0.41 0.67 0.52 0.90 1.34 1.24 1.26 1.35 3.03 2.44
Long-Term Debt to Equity		 0.45 0.35 0.59 0.40 0.84 1.28 1.10 1.13 1.24 2.90 2.32
Financial Leverage		 -0.19 -0.15 -0.13 -0.17 0.42 0.73 0.84 0.86 0.94 1.43 2.08
Leverage Ratio		 2.23 2.13 2.39 2.64 2.51 2.77 3.08 3.07 3.17 4.09 5.23
Compound Leverage Factor		 2.23 2.13 2.39 2.64 2.51 2.77 3.08 3.07 3.17 4.09 5.23
Debt to Total Capital		 31.68% 29.10% 40.19% 34.22% 47.48% 57.22% 55.30% 55.82% 57.43% 75.18% 70.91%
Short-Term Debt to Total Capital		 0.66% 4.30% 4.98% 7.93% 3.40% 2.64% 6.14% 6.05% 4.50% 3.10% 3.55%
Long-Term Debt to Total Capital		 31.02% 24.79% 35.21% 26.29% 44.08% 54.58% 49.16% 49.77% 52.92% 72.09% 67.36%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.75% 0.74% 0.54% 0.45% 0.10% 0.07% 0.07% 0.08% 0.08% 0.08% 0.05%
Common Equity to Total Capital		 67.57% 70.17% 59.27% 65.33% 52.42% 42.71% 44.62% 44.10% 42.49% 24.74% 29.04%
Debt to EBITDA		 2.48 1.04 1.29 1.08 5.56 14.44 2.37 2.19 2.19 40.66 3.38
Net Debt to EBITDA		 -0.83 -0.37 -0.22 -0.47 3.64 9.81 1.47 1.67 1.49 31.51 2.55
Long-Term Debt to EBITDA		 2.43 0.88 1.13 0.83 5.16 13.77 2.11 1.95 2.01 38.99 3.21
Debt to NOPAT		 4.51 1.97 12.16 1.73 11.36 -7.88 6.97 5.77 5.73 -9.47 5.96
Net Debt to NOPAT		 -1.51 -0.69 -2.03 -0.75 7.43 -5.35 4.32 4.41 3.91 -7.34 4.50
Long-Term Debt to NOPAT		 4.41 1.68 10.65 1.33 10.55 -7.52 6.20 5.14 5.28 -9.08 5.66
Altman Z-Score		 5.34 5.41 4.89 4.87 1.50 1.48 2.15 2.45 2.21 1.42 2.13
Noncontrolling Interest Sharing Ratio		 0.98% 1.07% 0.98% 0.78% 0.30% 0.18% 0.16% 0.17% 0.18% 0.24% 0.25%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.30 1.55 1.55 1.66 1.60 1.58 1.52 1.25 1.43 1.25 1.26
Quick Ratio		 1.07 1.35 1.37 1.36 1.26 1.28 1.20 0.87 1.04 0.91 0.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 918 1,601 4,124 3,814 -67,217 3,548 15,091 9,227 11,509 -3,485 9,876
Operating Cash Flow to CapEx		 256.71% 251.69% 500.00% 743.01% 982.06% 1,866.14% 1,665.67% 1,168.69% 1,146.40% 1,217.15% 1,079.79%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.51 0.59 0.62 0.66 0.32 0.34 0.41 0.45 0.47 0.51 0.53
Accounts Receivable Turnover		 4.31 3.95 3.51 3.75 3.89 5.25 5.19 4.79 4.33 4.46 4.35
Inventory Turnover		 2.81 4.04 5.00 5.48 2.94 3.70 5.32 4.94 4.64 10.48 6.73
Fixed Asset Turnover		 3.75 4.14 4.16 4.50 4.64 7.01 7.77 7.50 6.98 7.01 6.57
Accounts Payable Turnover		 1.93 3.08 3.07 3.12 3.73 4.56 3.92 3.66 3.69 7.97 4.92
Days Sales Outstanding (DSO)		 84.74 92.46 104.03 97.45 93.76 69.48 70.31 76.13 84.37 81.87 83.92
Days Inventory Outstanding (DIO)		 129.84 90.42 73.04 66.63 123.99 98.70 68.55 73.89 78.64 34.84 54.23
Days Payable Outstanding (DPO)		 189.18 118.59 118.71 116.83 97.98 79.96 93.10 99.80 99.05 45.80 74.18
Cash Conversion Cycle (CCC)		 25.40 64.29 58.36 47.25 119.76 88.22 45.76 50.22 63.96 70.91 63.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 12,183 13,986 10,517 10,942 82,271 72,294 63,593 61,185 56,613 54,858 52,548
Invested Capital Turnover		 1.39 1.48 1.70 2.10 0.56 0.55 0.68 0.74 0.76 0.87 0.90
Increase / (Decrease) in Invested Capital		 566 1,803 -3,469 425 71,329 -9,977 -8,701 -2,408 -4,572 -1,755 -2,310
Enterprise Value (EV)		 87,831 75,730 80,969 68,308 121,711 161,256 155,767 169,192 125,477 151,984 142,601
Market Capitalization		 89,914 77,921 82,193 71,397 91,038 126,784 128,120 139,068 98,294 113,461 108,526
Book Value per Share		 $8.55 $9.68 $7.17 $8.60 $31.67 $16.74 $16.19 $14.61 $14.46 $8.05 $9.07
Tangible Book Value per Share		 $3.58 $4.74 $2.24 $3.92 ($21.40) ($15.92) ($12.20) ($12.20) ($9.24) ($14.15) ($11.00)
Total Capital		 21,113 23,055 19,809 21,476 98,431 88,558 80,559 70,438 69,257 66,037 63,617
Total Debt		 6,689 6,708 7,962 7,349 46,733 50,676 44,553 39,320 39,772 49,649 45,111
Total Long-Term Debt		 6,550 5,716 6,975 5,646 43,387 48,336 39,605 35,056 36,653 47,603 42,850
Net Debt		 -2,241 -2,361 -1,330 -3,185 30,573 34,412 27,587 30,067 27,128 38,470 34,042
Capital Expenditures (CapEx)		 820 1,215 1,055 951 836 753 973 1,118 1,209 1,248 1,311
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1,733 -495 -534 6.00 -997 -2,379 -624 394 347 -2,807 -2,439
Debt-free Net Working Capital (DFNWC)		 2,537 5,855 6,278 8,765 14,396 13,452 16,342 9,647 12,627 8,052 8,234
Net Working Capital (NWC)		 2,398 4,863 5,291 7,062 11,050 11,112 11,394 5,383 9,508 6,006 5,973
Net Nonoperating Expense (NNE)		 -147 -1,103 -320 -708 652 2,566 -624 474 -1,103 3,693 511
Net Nonoperating Obligations (NNO)		 -2,241 -2,361 -1,330 -3,185 30,573 34,412 27,587 30,067 27,128 38,470 34,042
Total Depreciation and Amortization (D&A)		 621 551 1,025 823 3,434 10,380 10,686 10,276 9,760 9,600 4,011
Debt-free, Cash-free Net Working Capital to Revenue		 -10.47% -2.55% -2.57% 0.03% -3.81% -5.60% -1.35% 0.85% 0.77% -5.81% -5.06%
Debt-free Net Working Capital to Revenue		 15.32% 30.14% 30.22% 38.85% 55.06% 31.64% 35.23% 20.90% 28.06% 16.67% 17.09%
Net Working Capital to Revenue		 14.48% 25.03% 25.47% 31.30% 42.26% 26.13% 24.56% 11.66% 21.13% 12.43% 12.39%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.94 $2.67 $0.61 $3.01 $2.02 ($3.99) $3.15 $2.97 $3.88 ($4.41) $3.47
Adjusted Weighted Average Basic Shares Outstanding		 1.67B 1.67B 1.63B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B 2.04B
Adjusted Diluted Earnings per Share		 $0.93 $2.65 $0.61 $3.01 $2.01 ($3.99) $3.12 $2.95 $3.86 ($4.41) $3.46
Adjusted Weighted Average Diluted Shares Outstanding		 1.67B 1.67B 1.63B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B 2.04B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $2.02 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.67B 1.67B 1.63B 1.63B 2.26B 2.24B 2.18B 2.10B 2.02B 2.03B 2.04B
Normalized Net Operating Profit after Tax (NOPAT)		 1,484 3,404 2,412 4,239 4,112 -6,430 6,390 6,819 6,937 -5,240 7,566
Normalized NOPAT Margin		 8.96% 17.52% 11.61% 18.79% 15.73% -15.12% 13.78% 14.77% 15.41% -10.85% 15.70%
Pre Tax Income Margin		 12.54% 30.45% 24.70% 26.45% 19.03% -16.16% 17.46% 16.71% 18.75% -17.35% 19.36%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 151.87% 56.51% 264.31% 52.82% 77.43% -45.30% 62.67% 73.03% 59.01% -54.44% 71.51%
Augmented Payout Ratio		 151.87% 61.64% 517.54% 59.29% 288.41% -62.49% 152.31% 199.13% 123.12% -54.44% 71.51%

Quarterly Metrics And Ratios for Bristol Myers Squibb

This table displays calculated financial ratios and metrics derived from Bristol Myers Squibb's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 2,036,473,705.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 2,036,473,705.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.31
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.25% 0.62% 4.66% 8.69% 8.44% 7.54% -5.60% 0.56% 2.78% 1.30% 2.57%
EBITDA Growth		 -4.69% -5.53% -272.80% -9.53% -6.65% -50.34% 144.32% -28.31% -3.35% 19.17% -3.74%
EBIT Growth		 -3.26% -9.95% -515.74% -30.82% -21.57% -89.55% 125.79% 37.79% 85.80% 741.14% 9.06%
NOPAT Growth		 12.91% -23.32% -514.96% 4.83% -18.58% -84.80% 134.26% -17.80% 53.03% 403.60% -1.37%
Net Income Growth		 20.27% -12.99% -625.28% -18.92% -37.18% -95.69% 120.68% -22.03% 80.66% 1,327.63% 8.77%
EPS Growth		 24.00% -8.42% -650.47% -16.16% -35.48% -94.25% 120.37% -22.89% 80.00% 980.00% 9.17%
Operating Cash Flow Growth		 28.86% 28.61% -4.58% 23.26% 17.68% 4.40% -31.05% 68.40% 12.88% -55.53% -43.50%
Free Cash Flow Firm Growth		 16.57% 41.63% -411.26% -76.89% -74.24% -66.96% 201.58% 1,901.81% 562.66% 71.12% -59.30%
Invested Capital Growth		 -6.61% -7.47% 2.88% 2.41% -0.21% -3.10% -11.51% -15.57% -13.44% -4.21% -2.41%
Revenue Q/Q Growth		 -2.32% 4.66% 3.38% 2.83% -2.53% 3.78% -9.24% 9.53% -0.38% 2.29% -8.10%
EBITDA Q/Q Growth		 6.55% -9.49% -317.11% 143.21% 9.94% -51.85% 93.77% -30.11% 48.22% -40.63% 56.51%
EBIT Q/Q Growth		 14.95% -21.67% -787.93% 111.17% 30.33% -89.56% 1,597.14% -40.34% 75.73% -52.73% 120.04%
NOPAT Q/Q Growth		 -12.68% -19.35% -683.63% 125.50% -32.18% -84.95% 1,215.42% -38.80% 26.27% -50.45% 157.63%
Net Income Q/Q Growth		 -6.88% -8.89% -775.82% 114.14% -27.85% -93.74% 3,139.47% -46.67% 67.17% -50.57% 146.82%
EPS Q/Q Growth		 -6.06% -6.45% -777.01% 114.09% -27.71% -91.67% 2,300.00% -46.67% 68.75% -50.00% 142.59%
Operating Cash Flow Q/Q Growth		 151.78% -10.50% -33.35% -17.93% 140.37% -20.60% -55.98% 100.46% 61.12% -68.72% -44.07%
Free Cash Flow Firm Q/Q Growth		 137.36% 1.61% -263.97% 105.84% 164.56% 30.32% 404.17% 15.16% -12.42% -66.35% 19.91%
Invested Capital Q/Q Growth		 -3.80% -3.48% 9.85% 0.42% -6.27% -6.28% 0.32% -4.19% -3.90% 3.71% 2.21%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 76.42% 70.85% -33.85% 72.14% 72.93% 60.77% 71.24% 60.23% 66.72% 56.10% 69.41%
EBITDA Margin		 41.69% 36.05% -75.72% 31.82% 35.89% 16.65% 35.55% 22.68% 33.75% 19.59% 33.36%
Operating Margin		 17.13% 11.35% -96.38% 12.78% 16.06% 3.89% 29.54% 18.47% 24.60% 11.37% 28.47%
EBIT Margin		 19.49% 14.59% -97.06% 10.54% 14.09% 1.42% 26.52% 14.44% 25.48% 11.77% 28.19%
Profit (Net Income) Margin		 17.64% 15.35% -100.36% 13.80% 10.22% 0.62% 21.98% 10.70% 17.96% 8.68% 23.31%
Tax Burden Percent		 90.50% 105.26% 103.40% 130.95% 72.49% 43.43% 82.87% 74.06% 70.49% 73.81% 82.65%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.03% 100.06% 100.00% 99.86% 100.03%
Effective Tax Rate		 9.50% -5.26% 0.00% -30.95% 27.51% 56.57% 17.13% 25.94% 29.51% 26.12% 17.31%
Return on Invested Capital (ROIC)		 11.47% 9.13% -50.10% 12.61% 9.43% 1.46% 19.90% 11.33% 15.25% 7.54% 20.99%
ROIC Less NNEP Spread (ROIC-NNEP)		 12.26% 10.50% -60.62% 11.65% 8.95% 1.06% 19.22% 10.42% 15.46% 7.63% 20.92%
Return on Net Nonoperating Assets (RNNOA)		 11.83% 9.91% -92.87% 17.63% 13.72% 1.52% 47.06% 24.32% 31.70% 15.86% 39.66%
Return on Equity (ROE)		 23.31% 19.04% -142.97% 30.24% 23.14% 2.98% 66.96% 35.65% 46.95% 23.40% 60.65%
Cash Return on Invested Capital (CROIC)		 18.91% 19.54% -10.27% -9.98% -7.75% -6.25% 23.23% 27.51% 26.89% 18.39% 16.32%
Operating Return on Assets (OROA)		 9.24% 6.84% -45.72% 5.21% 7.23% 0.73% 13.19% 7.28% 12.84% 6.21% 15.28%
Return on Assets (ROA)		 8.37% 7.20% -47.28% 6.82% 5.24% 0.32% 10.94% 5.39% 9.05% 4.58% 12.63%
Return on Common Equity (ROCE)		 23.26% 19.00% -142.61% 30.17% 23.08% 2.97% 66.73% 35.54% 46.81% 23.34% 60.50%
Return on Equity Simple (ROE_SIMPLE)		 28.63% 0.00% -37.20% -38.37% -42.28% 0.00% 31.27% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 1,701 1,371 -8,005 2,041 1,385 208 2,742 1,678 2,119 1,050 2,705
NOPAT Margin		 15.51% 11.95% -67.46% 16.73% 11.64% 1.69% 24.48% 13.68% 17.34% 8.40% 23.54%
Net Nonoperating Expense Percent (NNEP)		 -0.78% -1.37% 10.52% 0.96% 0.48% 0.40% 0.67% 0.91% -0.21% -0.10% 0.07%
Return On Investment Capital (ROIC_SIMPLE)		 - 1.98% - - - 0.32% 4.08% 2.52% 3.14% 1.65% 4.19%
Cost of Revenue to Revenue		 23.58% 29.15% 133.85% 27.86% 27.07% 39.23% 28.76% 39.78% 33.28% 43.90% 30.59%
SG&A Expenses to Revenue		 18.27% 18.06% 19.95% 15.80% 16.68% 17.31% 14.14% 13.96% 14.64% 17.45% 14.07%
R&D to Revenue		 20.45% 21.59% 22.71% 23.76% 19.96% 25.85% 20.15% 21.03% 20.68% 20.68% 23.06%
Operating Expenses to Revenue		 59.28% 59.50% 62.53% 59.36% 56.87% 56.88% 41.70% 41.76% 42.12% 44.74% 40.93%
Earnings before Interest and Taxes (EBIT)		 2,137 1,674 -11,516 1,286 1,676 175 2,970 1,772 3,114 1,472 3,239
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 4,572 4,138 -8,984 3,882 4,268 2,055 3,982 2,783 4,125 2,449 3,833
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.94 3.34 6.61 4.87 6.05 6.95 7.04 5.33 4.88 5.88 6.09
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2.54 2.18 2.40 1.78 2.19 2.35 2.57 1.95 1.89 2.25 2.52
Price to Earnings (P/E)		 13.79 12.25 0.00 0.00 0.00 0.00 22.59 18.42 14.99 15.39 16.80
Dividend Yield		 4.11% 4.72% 4.31% 5.72% 4.63% 4.29% 4.01% 5.34% 5.53% 4.65% 4.15%
Earnings Yield		 7.25% 8.16% 0.00% 0.00% 0.00% 0.00% 4.43% 5.43% 6.67% 6.50% 5.95%
Enterprise Value to Invested Capital (EV/IC)		 2.46 2.22 2.49 2.06 2.48 2.77 2.91 2.43 2.42 2.71 2.90
Enterprise Value to Revenue (EV/Rev)		 3.21 2.79 3.40 2.76 3.06 3.15 3.36 2.69 2.55 2.96 3.22
Enterprise Value to EBITDA (EV/EBITDA)		 7.82 6.89 38.53 35.58 43.93 124.48 11.28 9.80 9.48 10.69 11.82
Enterprise Value to EBIT (EV/EBIT)		 16.72 14.87 0.00 0.00 0.00 0.00 26.21 19.46 15.27 15.29 16.24
Enterprise Value to NOPAT (EV/NOPAT)		 19.66 18.09 0.00 0.00 0.00 0.00 24.78 20.96 17.99 18.85 20.65
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.17 9.05 11.28 9.06 9.67 10.01 11.19 8.07 7.38 10.07 11.72
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.56 10.90 0.00 0.00 0.00 0.00 11.76 8.10 8.35 14.44 17.57
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.29 1.35 3.36 3.07 2.89 3.03 2.85 2.81 2.63 2.44 2.21
Long-Term Debt to Equity		 1.11 1.24 2.99 2.86 2.83 2.90 2.65 2.54 2.39 2.32 2.10
Financial Leverage		 0.97 0.94 1.53 1.51 1.53 1.43 2.45 2.33 2.05 2.08 1.90
Leverage Ratio		 3.07 3.17 3.99 3.83 4.00 4.09 5.63 5.48 5.32 5.23 4.76
Compound Leverage Factor		 3.07 3.17 3.99 3.83 4.00 4.09 5.63 5.48 5.32 5.23 4.77
Debt to Total Capital		 56.41% 57.43% 77.09% 75.43% 74.31% 75.18% 74.02% 73.77% 72.48% 70.91% 68.86%
Short-Term Debt to Total Capital		 8.20% 4.50% 8.57% 5.08% 1.61% 3.10% 5.29% 7.07% 6.67% 3.55% 3.57%
Long-Term Debt to Total Capital		 48.21% 52.92% 68.52% 70.34% 72.70% 72.09% 68.73% 66.70% 65.80% 67.36% 65.29%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.10% 0.08% 0.08% 0.08% 0.09% 0.08% 0.09% 0.08% 0.07% 0.05% 0.05%
Common Equity to Total Capital		 43.50% 42.49% 22.83% 24.50% 25.60% 24.74% 25.89% 26.15% 27.45% 29.04% 31.08%
Debt to EBITDA		 2.04 2.19 13.86 14.52 15.06 40.66 3.50 3.76 3.78 3.38 3.37
Net Debt to EBITDA		 1.62 1.49 11.36 12.58 12.51 31.51 2.65 2.69 2.48 2.55 2.55
Long-Term Debt to EBITDA		 1.74 2.01 12.32 13.54 14.73 38.99 3.25 3.40 3.44 3.21 3.20
Debt to NOPAT		 5.13 5.73 -12.22 -11.18 -10.67 -9.47 7.69 8.04 7.18 5.96 5.89
Net Debt to NOPAT		 4.08 3.91 -10.02 -9.68 -8.86 -7.34 5.82 5.76 4.70 4.50 4.45
Long-Term Debt to NOPAT		 4.38 5.28 -10.86 -10.43 -10.44 -9.08 7.14 7.27 6.52 5.66 5.58
Altman Z-Score		 2.16 1.97 1.13 1.46 1.69 1.72 1.93 1.60 1.64 1.84 2.20
Noncontrolling Interest Sharing Ratio		 0.21% 0.18% 0.25% 0.23% 0.26% 0.24% 0.35% 0.31% 0.30% 0.25% 0.25%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.18 1.43 1.11 1.16 1.24 1.25 1.28 1.21 1.27 1.26 1.42
Quick Ratio		 0.77 1.04 0.78 0.78 0.84 0.91 0.94 0.91 0.99 0.94 1.04
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 5,850 5,943 -9,746 569 1,507 1,963 9,899 11,400 9,984 3,360 4,029
Operating Cash Flow to CapEx		 1,389.18% 1,288.48% 997.89% 887.79% 1,725.62% 1,174.34% 751.54% 1,085.04% 1,972.19% 533.51% 318.16%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.47 0.47 0.47 0.49 0.51 0.51 0.50 0.50 0.50 0.53 0.54
Accounts Receivable Turnover		 4.51 4.33 4.44 4.32 4.45 4.46 4.48 4.18 4.28 4.35 4.81
Inventory Turnover		 4.84 4.64 8.89 9.27 8.96 10.48 5.20 5.56 5.59 6.73 6.62
Fixed Asset Turnover		 7.18 6.98 6.99 7.05 7.09 7.01 6.82 6.71 6.74 6.57 6.52
Accounts Payable Turnover		 4.03 3.69 7.38 7.39 8.23 7.97 3.89 3.52 4.39 4.92 4.36
Days Sales Outstanding (DSO)		 80.89 84.37 82.17 84.50 82.06 81.87 81.40 87.37 85.29 83.92 75.92
Days Inventory Outstanding (DIO)		 75.47 78.64 41.06 39.39 40.73 34.84 70.25 65.65 65.34 54.23 55.12
Days Payable Outstanding (DPO)		 90.50 99.05 49.46 49.37 44.36 45.80 93.74 103.64 83.22 74.18 83.73
Cash Conversion Cycle (CCC)		 65.86 63.96 73.77 74.52 78.43 70.91 57.91 49.38 67.40 63.97 47.31
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 58,656 56,613 62,188 62,448 58,534 54,858 55,031 52,726 50,669 52,548 53,707
Invested Capital Turnover		 0.74 0.76 0.74 0.75 0.81 0.87 0.81 0.83 0.88 0.90 0.89
Increase / (Decrease) in Invested Capital		 -4,149 -4,572 1,741 1,472 -122 -1,755 -7,157 -9,722 -7,865 -2,310 -1,324
Enterprise Value (EV)		 144,239 125,477 154,774 128,358 145,128 151,984 160,085 128,268 122,671 142,601 155,894
Market Capitalization		 114,256 98,294 109,076 82,925 103,736 113,461 122,441 92,978 90,553 108,526 122,252
Book Value per Share		 $13.88 $14.46 $8.13 $8.39 $8.46 $8.05 $8.57 $8.57 $9.11 $9.07 $9.85
Tangible Book Value per Share		 ($10.10) ($9.24) ($18.75) ($16.84) ($15.57) ($14.15) ($13.22) ($12.64) ($11.62) ($11.00) ($9.78)
Total Capital		 66,666 69,257 72,225 69,458 66,952 66,037 67,159 66,674 67,578 63,617 64,562
Total Debt		 37,604 39,772 55,677 52,389 49,752 49,649 49,711 49,185 48,978 45,111 44,460
Total Long-Term Debt		 32,137 36,653 49,487 48,858 48,674 47,603 46,157 44,470 44,469 42,850 42,152
Net Debt		 29,919 27,128 45,640 45,379 41,334 38,470 37,585 35,236 32,070 34,042 33,608
Capital Expenditures (CapEx)		 342 330 284 262 324 378 260 361 320 370 347
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,952 347 -633 503 -1,579 -2,807 -1,515 -3,194 -4,499 -2,439 -128
Debt-free Net Working Capital (DFNWC)		 9,637 12,627 9,037 7,156 6,515 8,052 10,267 10,409 12,003 8,234 10,358
Net Working Capital (NWC)		 4,170 9,508 2,847 3,625 5,437 6,006 6,713 5,694 7,494 5,973 8,050
Net Nonoperating Expense (NNE)		 -233 -391 3,904 357 170 132 280 365 -76 -35 27
Net Nonoperating Obligations (NNO)		 29,594 27,128 45,640 45,379 41,334 38,470 37,583 35,237 32,069 34,042 33,605
Total Depreciation and Amortization (D&A)		 2,435 2,464 2,532 2,596 2,592 1,880 1,012 1,011 1,011 977 594
Debt-free, Cash-free Net Working Capital to Revenue		 4.34% 0.77% -1.39% 1.08% -3.33% -5.81% -3.18% -6.70% -9.37% -5.06% -0.26%
Debt-free Net Working Capital to Revenue		 21.45% 28.06% 19.85% 15.39% 13.73% 16.67% 21.55% 21.82% 24.99% 17.09% 21.36%
Net Working Capital to Revenue		 9.28% 21.13% 6.25% 7.79% 11.46% 12.43% 14.09% 11.94% 15.60% 12.39% 16.60%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.94 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.21 $0.64 $1.08 $0.54 $1.31
Adjusted Weighted Average Basic Shares Outstanding		 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B 2.04B 2.04B 2.04B
Adjusted Diluted Earnings per Share		 $0.93 $0.87 ($5.89) $0.83 $0.60 $0.05 $1.20 $0.64 $1.08 $0.54 $1.31
Adjusted Weighted Average Diluted Shares Outstanding		 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B 2.04B 2.04B 2.04B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.03B 2.02B 2.03B 2.03B 2.03B 2.03B 2.04B 2.04B 2.04B 2.04B 2.04B
Normalized Net Operating Profit after Tax (NOPAT)		 1,701 912 -8,005 1,091 1,385 336 2,742 1,678 2,119 1,050 2,705
Normalized NOPAT Margin		 15.51% 7.95% -67.46% 8.94% 11.64% 2.72% 24.48% 13.68% 17.34% 8.40% 23.54%
Pre Tax Income Margin		 19.49% 14.59% -97.06% 10.54% 14.09% 1.42% 26.52% 14.45% 25.48% 11.76% 28.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 56.96% 59.01% -77.59% -73.22% -66.30% -54.44% 90.29% 97.79% 82.72% 71.51% 69.73%
Augmented Payout Ratio		 148.14% 123.12% -157.54% -134.50% -66.30% -54.44% 90.29% 97.79% 82.72% 71.51% 69.73%

Financials Breakdown Chart

Key Financial Trends

Bristol Myers Squibb (NYSE: BMY) has shown solid short‑term profitability and ongoing liquidity while continuing to invest in its R&D pipeline. Below is a concise, data‑driven view of the four most recent annual windows, focusing on four years of quarterly results (income statement, balance sheet, and cash flow) to highlight notable trends for retail investors.

  • Strong year‑over‑year net income for Q4 2025: Net income attributable to common shareholders was $1,087,000,000 in Q4 2025, up from $72,000,000 in Q4 2024. This reflects a substantial improvement in profitability for the latest quarter.
  • Stable top‑line with quarterly revenue near a high watermark: Operating revenue in Q4 2025 was $12,502,000,000, versus $12,342,000,000 in Q4 2024, indicating continued strong sales.
  • Higher operating profitability in Q4 2025: Total operating income rose to $1,421,000,000 in Q4 2025 from $480,000,000 in Q4 2024, signaling improved operating leverage.
  • Consistent shareholder returns via dividends: The quarterly dividend per share remained at $0.62 (e.g., Q1–Q4 2025), providing a steady income stream for investors.
  • Robust R&D investment supporting the pipeline: R&D expense in Q4 2025 was $2,586,000,000, underscoring ongoing commitment to product development and future growth.
  • Solid liquidity position: Cash & equivalents around $15.7B on the balance sheet in mid‑2025 (Q3 2025), supporting near‑term liquidity and operational flexibility.
  • Positive cash flow from operations, but at a lower YoY level: Net cash from continuing operating activities in Q4 2025 was $1,974,000,000, which is positive but below the prior‑year quarter’s level (~$4.44B in Q4 2024), indicating seasonality or other timing effects rather than a deterioration in cash generation.
  • Balance sheet size and stability: Total assets about $96.9B and total equity around $18.6B in mid‑2025 (e.g., Q3 2025 figures), reflecting a large but stable asset base and equity cushion.
  • Margin compression versus a year ago: Gross margin declined to roughly 56% in Q4 2025 (gross profit $7.014B on $12.502B revenue) from about 61% in Q4 2024, indicating compression in gross profitability.
  • Significant leverage remains: In Q3 2025, long‑term debt was about $44.47B and total liabilities were about $78.29B, yielding substantial leverage that adds interest costs and financing considerations for the business.
  • Substantial financing outflows in 2025: Net cash from financing activities were negative across several quarters in 2025 (e.g., large debt repayments), contributing to overall net cash outflows despite positive operating results.
05/07/26 08:37 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Bristol Myers Squibb's Financials

When does Bristol Myers Squibb's fiscal year end?

According to the most recent income statement we have on file, Bristol Myers Squibb's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Bristol Myers Squibb's net income changed over the last 10 years?

Over the last 10 years, Bristol Myers Squibb's net income changed from $1.63 billion in 2015 to $7.06 billion in 2025, a change of 332.6%. See Bristol Myers Squibb's forecast for analyst expectations on what’s next for the company.

What is Bristol Myers Squibb's operating income?
Bristol Myers Squibb's total operating income in 2025 was $10.00 billion, based on the following breakdown:
  • Total Gross Profit: $30.54 billion
  • Total Operating Expenses: $20.54 billion
How has Bristol Myers Squibb's revenue changed over the last 10 years?

Over the last 10 years, Bristol Myers Squibb's total revenue changed from $16.56 billion in 2015 to $48.19 billion in 2025, a change of 191.0%.

How much debt does Bristol Myers Squibb have?

Bristol Myers Squibb's total liabilities were at $71.53 billion at the end of 2025, a 6.1% decrease from 2024, and a 312.9% increase since 2015.

How much cash does Bristol Myers Squibb have?

In the past 10 years, Bristol Myers Squibb's cash and equivalents has ranged from $2.39 billion in 2015 to $14.55 billion in 2020, and is currently $10.21 billion as of their latest financial filing in 2025.

How has Bristol Myers Squibb's book value per share changed over the last 10 years?

Over the last 10 years, Bristol Myers Squibb's book value per share changed from 8.55 in 2015 to 9.07 in 2025, a change of 6.1%.


Related Companies

Financial statements for NYSE:BMY last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel